Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Thu, 02.11.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023 Ladenburg, Germany, 2 November 2023 – Heidelberg Pharma AG (FSE: HPHA) will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society o [ … ]
Technical analysis
To the publication
Thu, 12.10.2023       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023 HDP-101 clinical trial in Europe and US continues with adjusted protocol and larger number of study sites in Europe; fifth patient cohort initiated at 100 µg/kg dosing Patient from third cohort continues to be dosed and shows stable disease Divestment of minorit [ … ]
Technical analysis
To the publication
Tue, 19.09.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101 First four patient cohorts and dose levels have been completed and proved to be safe and well tolerated Enrollment for fifth cohort with a dose of 100 µg/kg has already started Patient from third cohort continues to be dosed and shows no pr [ … ]
Technical analysis
To the publication
Tue, 08.08.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma’s Partner Takeda Reached Development Milestone Ladenburg, Germany, 8 August 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that its partner Takeda reached a development milestone for starting a GLP (Good Laboratory Practice) toxicology study for an Antibody Targeted Amanitin Conjugate. Upon achievement of  [ … ]
Technical analysis
To the publication
Thu, 13.07.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe Patient from 3rd cohort continues to be dosed and shows stable disease Partnership with Magenta terminated due to clinical events and strategy change  [ … ]
Technical analysis
To the publication
Thu, 13.07.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business Clinical trial with HDP-101 continues with adjusted protocol and larger number of study sites in Europe Patient from 3rd cohort continues to be dosed and shows stable disease Partnership with Magenta terminated due to clinical events and strategy change  [ … ]
Technical analysis
To the publication
Thu, 29.06.2023       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about [ … ]
Technical analysis
To the publication
Thu, 29.06.2023       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about [ … ]
Technical analysis
To the publication
Thu, 25.05.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2023 Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual [ … ]
Technical analysis
To the publication
Thu, 25.05.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2023 Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.